Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancers
worldwide. More than half of patients with HNSCC eventually experience disease …

Epidermal growth factor receptor (EGFR) overexpression is common in head and neck
squamous cell carcinoma. Targeted therapy specifically directed towards EGFR has been …

Inflammation often exists in the tumor microenvironment and is induced by inflammatory
mediators (cytokines, chemokines, and growth factors) produced by the tumor, stroma, and …

Treatment of squamous cell carcinoma of the head and neck (SCCHN) has evolved greatly
in the last two decades, owing to the integration of chemotherapy, advances in …

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin
cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) …

Head and neck squamous cell carcinoma (HNSCC) is a common malignancy with high rates
of mortality and morbidity. Beginning with cetuximab, investigators continue to optimize …

During the past decade, there has been a significant increase in knowledge regarding the
molecular biology and epigenetics of head and neck squamous cell carcinoma (HNSCC) …

Current algorithms for the clinical management of patients with squamous cell carcinoma of
the head and neck (HNSCC) are based on a stage-dependent strategy where all patients at …

Head and neck squamous cell carcinomas (HNSCCs) arise in the mucosal linings of the
upper aerodigestive tract and are unexpectedly heterogeneous in nature. Classical risk …

Head and neck squamous carcinoma (HNSCC) is the sixth most prevalent cancer and one
of the most aggressive malignancies worldwide. Despite continuous efforts to identify …